Mexico positions itself at the forefront of biomedical innovation thanks to the collaboration between Fundación Carlos Slim and Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán (INCMNSZ).
This alliance promotes the development and application of CAR-T cell therapies, an innovation capable of recognizing and eliminating cancer cells, especially in leukemia and other hematological cancers. The agreement includes the creation of a specialized laboratory to process CAR-T cells, accelerating research and its clinical application. The goal is to democratize access to these therapies, reducing costs and benefiting more patients, in contrast to the high prices that persist in other countries.
This breakthrough is inspired by the scientific principles that led to the 2025 Nobel Prize in Medicine, awarded for the discovery of regulatory T cells, which are essential for understanding the immune system and developing treatments for autoimmune diseases and transplant rejection. Both lines of research converge towards a more precise and balanced medicine, where science not only fights disease but also teaches the body to heal.
